Under a tenth of patients eligible to benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it releases its initial advice on the therapies.
Considering over a billion individuals worldwide currently classified as obese, it is urging increased and just availability to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"The new guidelines recognises that obesity is a lifelong illness that can be managed with holistic and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant obstacles to universal availability to the jabs that can aid individuals in losing considerable weight, explains the agency.
Weight-Loss Drug Supply Crisis
Despite the present best projected case, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the health organization.
The recommendation encourages countries and companies to widen availability, by strategies such as patent sharing.
A patent on the active ingredient – the main ingredient of the drug Wegovy – is due to expire in several nations in 2026.
How Weight-Loss Drugs Function
These medications imitate a body's own hormone to delay gastric emptying, suppress the appetite and enhance feelings of fullness so people eat less.
Patients typically begin shedding pounds after several weeks of starting on the once-weekly jabs.
Evidence indicates people may see weight return within a year of halting the drug, as their usual appetite come back.
Being carrying excess weight elevates your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity affects individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.
